S1800E: LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study) | WVU Cancer Institute Clinical Research Unit

LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)

Principal Investigator

Almubarak, Mohammed

Phase

II/III

Age Group

Adult

Applicable Disease Site

Lung Cancer

Participating Institutions

Camden Clark Medical Center

Mary Babb Randolph Cancer Center

Contacts